Party Drug Ketamine (Special K) Likely To Become Anti-Depression Medicine
The drug Ketamine, known in the party scene as "Special K," could have a future in depression treatment. Pharmaceutical companies are racing to create a patentable version of the drug and researchers are trying to learn more about the effects it has on the brain. Ketamine works by blocking the signalling molecule NMDA, which is a component of the glutamate pathway. This pathway is involved with memory and cognition, psychiatrist James Murrough at the Mount Sinai Hospital in New York City, explained to Nature magazine.
- Dr. James Murrough, Assistant Professor, Psychiatry, Neuroscience, Icahn School of Medicine at Mount Sinai

Changes in Microbiome Predict Risk for Sexually Transmitted Disease
Jan 15, 2025 View All Press Releases
Breakthrough Treatment for Liver Cancer Shows Big Promise in Global Study
Jan 09, 2025 View All Press Releases
Mount Sinai Researchers Create AI Tool to Democratize Access to Cancer Immunotherapy
Jan 06, 2025 View All Press Releases